Ожирение как фактор онкологического риска. Обзор литературы

Информация только для специалистов в сфере медицины, фармации и здравоохранения!
 1938

Ожирение как фактор онкологического риска. Обзор литературы

Журнал "Медицинский совет" №4, 2019

DOI: https://doi.org/10.21518/2079-701X-2019-4-94-102

Салухов В.В., Кадин Д.В.Федеральное государственное бюджетное военное образовательное учреждение высшего образования «Военно-медицинская академия имени С.М. Кирова» Министерства обороны Российской Федерации

Ожирение становится все более распространенным и проявляет себя как фактор риска многих неинфекционных заболеваний. За последние десятилетия получены значительные массивы информации относительно связи ожирения с риском развития некоторых злокачественных новообразований, в особенности желудочно-кишечного тракта и женской половой системы. В данной обзорной статье обсуждаются вопросы достоверности имеющихся статистических данных, влияние типа опухоли, возрастных и гендерных особенностей на онкологический риск, освещаются традиционные и перспективные гипотезы о возможной роли ожирения в онкогенезе. В сжатом виде представлены сведения о влиянии ожирения на течение развившейся онкопатологии и о роли снижения массы тела в снижении онкологического риска.

Obesity as an oncological risk factor. Literature review

Vladimir V. Salukhov, Dmitry V. Kadin, Federal State Budgetary Military Educational Institution of Higher Education Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Obesity is becoming increasingly common and is becoming a risk factor for many non-communicable diseases. Over the past decades, considerable information has been gathered on the relationship between obesity and the risk of certain malignant neoplasms, particularly the gastrointestinal tract and the female genital system. This review article discusses the reliability of available statistical data, the impact of the type of tumor, age and gender peculiarities on cancer risk, highlights traditional and prospective hypotheses about the possible role of obesity in oncogenesis. The data on the influence of obesity on the course of developed oncopathology and the role of weight loss in reducing cancer risk are presented in a concise form.

Загрузить файл в формате PDF


Литература / References

  1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 192 million participants. Lancet Lond Engl. 2016 Apr 2;387(10026):1377–96.
  2. Glade M.J. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutr Burbank Los Angel Cty Calif. 1999 Jun;15(6):523–6.
  3. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet Lond Engl. 2008 Feb 16;371(9612):569–78.
  4. Dobbins M., Decorby K., Choi B.C.K. The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536.
  5. Arnold M., Pandeya N., Byrnes G., Renehan P.A.G., Stevens G.A., Ezzati P.M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015 Jan;16(1):36–46.
  6. Yang X.R., Chang-Claude J., Goode E.L., Couch F.J., Nevanlinna H., Milne R.L., et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011 Feb 2;103(3):250–63.
  7. Morikawa T., Kuchiba A., Lochhead P., Nishihara R., Yamauchi M., Imamura Y., et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res. 2013 Mar 1;73(5):1600–10.
  8. IARC. Weight Control and Physical Activity [Internet]. [cited 2019 Apr 13]. Available from: http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Weight-Contro....
  9. Bjørge T., Engeland A., Tverdal A., Smith G.D. Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. Am J Epidemiol. 2008 Jul 1;168(1):30–7.
  10. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Nov 20;31(33):4229–34.
  11. Yang B., Petrick J.L., Kelly S.P., Graubard B.I., Freedman N.D., McGlynn K.A. Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort. Int J Cancer. 2017 15;141(2):271–8.
  12. Vrieling A., Buck K., Kaaks R., Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat. 2010 Oct;123(3):641–9.
  13. Bonn S.E., Wiklund F., Sjölander A., Szulkin R., Stattin P., Holmberg E., et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control CCC. 2014 Aug;25(8):933–43.
  14. Murphy N., Cross A.J., Abubakar M., Jenab M., Aleksandrova K., Boutron-Ruault M.-C., et al. A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS Med. 2016 Apr;13(4):e1001988.
  15. Keum N., Lee D.H., Kim R., Greenwood D.C., Giovannucci E.L. Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies. Ann Oncol Off J Eur Soc Med Oncol. 2015 Jun;26(6):1101–9.
  16. Lennon H., Sperrin M., Badrick E., Renehan A.G. The Obesity Paradox in Cancer: a Review. Curr Oncol Rep. 2016;18(9):56.
  17. Locke A.E., Kahali B., Berndt S.I., Justice A.E., Pers T.H., Day F.R., et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197–206.
  18. Dixon S.C., Nagle C.M., Thrift A.P., Pharoah P.D., Pearce C.L., Zheng W., et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016;45(3):884–95.
  19. Carreras-Torres R., Johansson M., Haycock P.C., Wade K.H., Relton C.L., Martin R.M., et al. Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PloS One. 2017;12(6):e0177875.
  20. Берштейн Л.М. Внегонадная продукция эстрогенов (роль в физиологии и патологии). Санкт-Петербург: Наука; 1998. 172 p.
  21. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003 Aug 20;95(16):1218–26.
  22. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9(4):e1001200.
  23. Crosbie E.J., Zwahlen M., Kitchener H.C., Egger M., Renehan A.G. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010 Dec;19(12):3119–30.
  24. Bray G.A., Bouchard C., editors. Handbook of Obesity, Two-Volume Set: Handbook of Obesity - Volume 2: Clinical Applications, Fourth Edition. 4 edition. Boca Raton: CRC Press; 2014. 528 p.
  25. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215–24.
  26. Ritte R., Lukanova A., Berrino F., Dossus L., Tjønneland A., Olsen A., et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res BCR. 2012 May 14;14(3):R76.
  27. Powell D.R., Suwanichkul A., Cubbage M.L., DePaolis L.A., Snuggs M.B., Lee P.D. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem. 1991 Oct 5;266(28):18868–76.
  28. Renehan A.G., Zwahlen M., Minder C., O’Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet Lond Engl. 2004 Apr 24;363(9418):1346–53.
  29. Watts E.L., Perez-Cornago A., Appleby P.N., Albanes D., Ardanaz E., Black A., et al. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. Int J Cancer. 2019 Mar 15.
  30. Mattu H.S., Randeva H.S. Role of adipokines in cardiovascular disease. J Endocrinol. 2013 Jan;216(1):T17-36.
  31. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012 Aug;33(4):547–94.
  32. Brenner D.R., Scherer D., Muir K., Schildkraut J., Boffetta P., Spitz M.R., et al. A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2014 Sep;23(9):1729–51.
  33. Zhang Y., Daquinag A., Traktuev D.O., Amaya-Manzanares F., Simmons P.J., March K.L., et al. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009 Jun 15;69(12):5259–66.
  34. Zhang X.H.-F., Jin X., Malladi S., Zou Y., Wen Y.H., Brogi E., et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013 Aug 29;154(5):1060–73.
  35. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010 Aug 26;29(34):4741–51.
  36. Rubinstein M.R., Wang X., Liu W., Hao Y., Cai G., Han Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013 Aug 14;14(2):195–206.
  37. Hourdequin K.C., Schpero W.L., McKenna D.R., Piazik B.L., Larson R.J. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2013 Dec;24(12):2952–62.
  38. Friedman A.M., Hemler J.R., Rossetti E., Clemow L.P., Ferrante J.M. Obese women’s barriers to mammography and pap smear: the possible role of personality. Obes Silver Spring Md. 2012 Aug;20(8):1611–7.
  39. Reynolds A. Obesity and medical imaging challenges. Radiol Technol. 2011 Feb;82(3):219–39.
  40. Bañez L.L., Hamilton R.J., Partin A.W., Vollmer R.T., Sun L., Rodriguez C., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21;298(19):2275–80.
  41. Sjöström L., Gummesson A., Sjöström C.D., Narbro K., Peltonen M., Wedel H., et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009 Jul;10(7):653–62.
  42. Adams T.D., Gress R.E., Smith S.C., Halverson R.C., Simper S.C., Rosamond W.D., et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753–61.
  43. Rodriguez C., Freedland S.J., Deka A., Jacobs E.J., McCullough M.L., Patel A.V., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007 Jan;16(1):63–9.
  44. Fabian C.J., Kimler B.F., Donnelly J.E., Sullivan D.K., Klemp J.R., Petroff B.K., et al. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10% weight loss in postmenopausal women. Breast Cancer Res Treat. 2013 Nov;142(1):119–32.
  45. Hursting S.D., Dunlap S.M., Ford N.A., Hursting M.J., Lashinger L.M. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab. 2013 Mar 7;1(1):10.
  46. Thomson C.A., Horn L.V., Caan B.J., Aragaki A.K., Chlebowski R.T., Manson J.E., et al. Cancer Incidence and Mortality during the Intervention and Postintervention Periods of the Women’s Health Initiative Dietary Modification Trial. Cancer Epidemiol Prev Biomark. 2014 Dec 1;23(12):2924–35.
  47. Lv M., Zhu X., Wang H., Wang F., Guan W. Roles of Caloric Restriction, Ketogenic Diet and Intermittent Fasting during Initiation, Progression and Metastasis of Cancer in Animal Models: A Systematic Review and Meta-Analysis. PLOS ONE. 2014 Dec 11;9(12):e115147.
  48. Kang H.C., Chung D.E., Kim D.W., Kim H.D. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004 Sep;45(9):1116–23.
  49. Scafoglio C.R., Villegas B., Abdelhady G., Bailey S.T., Liu J., Shirali A.S., et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018 Nov 14;10(467).
  50. Pischon T., Nimptsch K. Obesity and Cancer. Springer; 2016. 258 p. 




Последние статьи